Endo Pharmaceuticals is a top 50 pharma company specialising in brand pharmaceuticals for the treatment of pain, urology, oncology, CNS and derma products. Endo Pharmaceuticals makes up the fourth quarter of Endo Health Solutions alongside the other brands of the company AMS, Healthtronics and Qualitest.
The company is primarily based in the US and is behind two blockbuster products of recent times Percodan® and Percocet®, it also markets the top selling pain management treatment Voltaren gel in the USA.
Endo Pharmaceuticals has a history that dates back to 1920; it was in that year that ‘Intravenous products of America’ was established which then changed its name to Endo Products. Later in 1950 after the first launch of Percodan, Endo products were acquired by DuPont who later re-established Endo Products as a separate entity to its company. It was in 1997 that Endo Pharmaceuticals officially set up operations alone as it acquired some essential products and assets from The DuPont Merck Pharmaceutical Company.
Endo Pharmaceuticals main therapeutic areas of interest are as below; the company has both marketed and late stage products in these areas;
- Postherpetic Neuralgia (PHN)
- Chronic Pain
- Non-muscle Invasive Bladder Cancer
- Prostate Cancer
- Central Precocious Puberty (CPP)
Since Endo Pharmaceuticals formerly branched off it entered into a series of licensing and acquisition agreements which included licensing Lidoderm from Hind Healthcare and merging with Algos Pharmaceuticals. This latter merger led to the company becoming publicly listed traded company on NASDAQ. Endo Pharmaceuticals re- affirmed its position in the transdermal market by taking exclusive licences to a transdermal sufentanil patch from DURECT Corporation in 2005 and added further supportive oncology care products via the acquisition of RxKintetix Inc. The partnerships carried on with the takeover of Indevus Pharmaceuticals and licensing agreement with big pharma Novartis for the US marketing rights Voltaren gel ®.
Endo Pharmaceuticals has openly said a blend of internal R&D, licensing and M&A’s continue to supply it with a plentiful flow of products. The company has a corporate development team employed who manage and evaluate all incoming opportunities and negotiate with potential partners to sign strategic alliance deals, licensing agreements and equity investment transactions.
Endo Pharmaceuticals is often present at a large number of partnering events throughout the year.
Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Events with Endo Pharmaceuticals presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Endo Pharmaceuticals in person visit Current Partnering’s Event calendar.
Contacting Endo Pharmaceuticals for partnering
Endo Pharmaceuticals can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Endo Pharmaceuticals Kabi’s business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. Email contact to a named individual view the list of contacts at Endo Pharmaceuticals’ website for details.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Endo Pharmaceuticals’ business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Endo Pharmaceuticals’ LinkedIn page here.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the form available on the Endo Pharmaceutical website for potential partnering opportunities.
Available reports from Current Partnering
Report: Partnering Deals and Alliances with Endo Pharmaceuticals
Available resources for deal coverage for Endo Pharmaceuticals
Read: more on Endo company profile, recent partnering, M&A and financing news and articles
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk